NYT: Mediocre COVID-19 Drug Will Still Be a Blockbuster

NYT: Mediocre COVID-19 Drug Will Still Be a Blockbusterhttps://blogs.mercola.com:443/sites/vitalvotes/archive/2020/10/29/nyt-mediocre-covid19-drug-will-still-be-a-blockbuster.aspxGilead Sciences’ COVID-19 treatment drug, remdesivir, has already brought in $873 million since its emergency use authorization, making it the company’s second best-selling drug for the third quarter. The thing is, it’s a “mediocre”enCommunityServer 2008.5 SP1 (Debug Build: 31106.3070)re: NYT: Mediocre COVID-19 Drug Will Still Be a Blockbusterhttps://blogs.mercola.com:443/sites/vitalvotes/archive/2020/10/29/nyt-mediocre-covid19-drug-will-still-be-a-blockbuster.aspx?ShowAllComments=True#103559410/30/2020 5:54:27 AM24451277-a5aa-4add-96dc-64081bfd86fa:1035594JGB123<p>I think that I read Donald Trump received this drug... All for naught?</p>